ArticleJournal of advanced research2026
ALKBH5 modulates COL5A1 mRNA stability via m6A demethylation to promote tobacco carcinogen NNK-induced lung cancer occurrence and progression.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), has been extensively studied for its carcinogenic role in lung cancer. However, the involvement of N6-methyladenosine (m6A) methylation in NNK-induced carcinogenesis remains unclear.
objectivesThe aim of this study is to investigatewhether NNK promotes lung carcinogenesis by dysregulating m6A methylation, focusing on the demethylase ALKBH5 and its target COL5A1.
methodsLevels of m6A were analyzed in NNK-exposed (100 mg/L, 24 h) Beas-2B bronchial epithelial cells, NNK-induced malignant-transformed Beas-2B (2B-NNK) cells, and paired lung tumor tissues. Methylated RNA immunoprecipitation sequencing, RNA sequencing, and bioinformatics identified COL5A1 as a key target. We performed proliferation, apoptosis, migration and invasion experiments involving COL5A1 and ALKBH5 knockdown and COL5A1 stability experiments. We then overexpressed COL5A1 and knocked down ALKBH5 for phenotypic rescue experiments.
resultsLevels of m6A were significantly reduced in NNK-exposed Beas-2B cells, 2B-NNK cells, and human lung tumor tissues. COL5A1 exhibited hypomethylation and overexpression in 2B-NNK cells. COL5A1 knockdown suppressed 2B-NNK cell proliferation, migration, and invasion, while increasing apoptosis. The m6A demethylase ALKBH5 was upregulated in 2B-NNK cells. Its knockdown elevated global m6A levels, reduced COL5A1 mRNA stability, and reversed malignant phenotypes. COL5A1 overexpression also enhanced the proliferation, migration, and invasion abilities of 2B-NNK cells, whereas concurrent downregulation of ALKBH5 expression resulted in the restoration of these enhancements.
conclusionALKBH5 drives NNK-induced lung cancer via m6A demethylation of COL5A1, promoting tumor progression. Targeting the ALKBH5-COL5A1 axis may offer therapeutic strategies against tobacco-related cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.